Incyte (INCY) PT Bumped to $115 at Leerink as Gilead's (GILD) Momelotinib Disappoints
- Noble Energy (NBL) to Acquire Clayton Williams Energy (CWEI) for $2.7B in Cash and Stock
- Nasdaq hits record; bank earnings validate Wall St. rally
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
- Time (TIME) Said to Soon Begin Discussions with Interested Buyers - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and bumped his price target on Incyte (NASDAQ: INCY) to $115.00 (from $101.00) as Gilead Sciences' (NASDAQ: GILD) momelotinib disappoints.
Schmidt commented, "Today GILD (MP) reported top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis (MF): SIMPLIFY-1 and SIMPLIFY-II. Results from both trials are disappointing, in our view making it highly unlikely that GILD would be able to obtain regulatory approval. Removal of this uncertainty on the revenue outlook of INCY's key commercial product (see our recent deep-dive here: LINK), combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. While we assumed only a modest success probability for momelotinib, our prior scenario analysis suggested 7-22% downside potential to INCY's valuation in a rage of momelotinib success scenarios. Raising our PT to $115 (from $101)."
Shares of Incyte closed at $100.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Tiffany & Co. (TIF) to Market Perform; Demand Trends Stabilizing
- KLR Group Upgrades Sanchez Energy (SN) to Buy
- UPDATE: RBC Capital Upgrades Colfax Corporation (CFX) to Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!